Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001011703 | SCV001172056 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-09-07 | criteria provided, single submitter | clinical testing | The p.P488L variant (also known as c.1463C>T), located in coding exon 14 of the NF2 gene, results from a C to T substitution at nucleotide position 1463. The proline at codon 488 is replaced by leucine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV001759691 | SCV001995417 | uncertain significance | not provided | 2020-01-03 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV001800918 | SCV002044895 | uncertain significance | Neurofibromatosis, type 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001800918 | SCV002155070 | uncertain significance | Neurofibromatosis, type 2 | 2023-07-25 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 819284). This variant has not been reported in the literature in individuals affected with NF2-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.01%). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 488 of the NF2 protein (p.Pro488Leu). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
All of Us Research Program, |
RCV001800918 | SCV004825647 | uncertain significance | Neurofibromatosis, type 2 | 2023-05-31 | criteria provided, single submitter | clinical testing |